drugset / Trial / NCT05755997
CERebrolysin In CADASIL
Phase 2
Active not recruiting
30 enrolled
Ever Neuro Pharma GmbH
XClinical GmbH · collabidv Datenanalyse & Versuchsplanung · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to Placebo in patients with genetically proven CADASIL. In addition, a traditional approach will be taken based on an evaluation of the separate risk and benefit domains in comparison with placebo.
Timeline
- Start
- 2023-11-29
- Primary completion
- 2026-03-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cerebrolysin | Peptide | 40 ml | — |